Foresee Pharmaceuticals Valuation
Is 6576 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 6576 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 6576's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 6576's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6576?
Key metric: As 6576 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 6576's PS Ratio? | |
|---|---|
| PS Ratio | 33x |
| Sales | NT$327.18m |
| Market Cap | NT$11.22b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 32x |
| Enterprise Value/EBITDA | -13.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 6576's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.2x | ||
4167 Savior Lifetec | 5.2x | n/a | NT$6.5b |
3705 YungShin Global Holding | 2x | n/a | NT$15.4b |
1760 Panion & Bf Biotech | 3.8x | 7.5% | NT$7.7b |
1720 Standard Chemical & Pharmaceutical | 1.7x | n/a | NT$11.5b |
6576 Foresee Pharmaceuticals | 33x | n/a | NT$11.2b |
Price-To-Sales vs Peers: 6576 is expensive based on its Price-To-Sales Ratio (33x) compared to the peer average (3.2x).
Price to Sales Ratio vs Industry
How does 6576's PS Ratio compare vs other companies in the TW Pharmaceuticals Industry?
Price-To-Sales vs Industry: 6576 is expensive based on its Price-To-Sales Ratio (33x) compared to the TW Pharmaceuticals industry average (4.9x).
Price to Sales Ratio vs Fair Ratio
What is 6576's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 33x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6576's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
YungShin Global Holding
NT$15.4b
Through its subsidiaries, invests in, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicines, and cosmetics in Taiwan, Mainland China, Japan, and the United States.
3705
NT$57.90
7D
8.2%
1Y
27.1%
Winston Medical Supply
NT$1.6b
Winston Medical Supply Co.,Ltd. develops, manufactures, and distributes pharmaceuticals, nutrition supplements, and cosmeceutical products.
6817
NT$88.30
7D
-1.6%
1Y
-13.4%
RBC Bioscience
NT$254.3m
Researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia.
6848
NT$19.60
7D
-0.5%
1Y
29.8%